Molecular Pharmacology (USA), Ltd. (MLPH) Stock Analysis
DELISTED 2026
What happened to Molecular Pharmacology (USA), Ltd. (MLPH) stock?
Molecular Pharmacology (USA), Ltd. (MLPH) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- April 2026
- Last recorded price (historical):
- $0.0322 (last quote on record before the April 2026 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Molecular Pharmacology (USA), Ltd. (MLPH). Molecular Pharmacology (USA) Limited is a development stage company focused on pain and inflammation management products. Their lead product, Tripeptofen, targets everyday pain and is available in various formulations.
Last analyzed: Mar 17, 2026Molecular Pharmacology (USA), Ltd. (MLPH) Healthcare & Pipeline Overview
MLPH OTC Market Information
MLPH trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy MLPH shares?
No. MLPH stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for MLPH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MLPH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Molecular Pharmacology (USA), Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.